Ovette Villavicencio
Ophthalmology · Tucson, AZNPI 1972814374
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Glaukos Corporation at 24.1% of the total.
Across 183 payments — averaging $35.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Alcon$1K
- Sun Pharmaceutical Industries Inc.$915
- Novartis$528
- Johnson & Johnson Surgical Vision, Inc.$390
- Dompe US, Inc.$359
- plus $2K from 18 others
Across 6 payments — averaging $66,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$401K
What the payments were for
- Food & beverage$6,42499%
- Education$180%
- Gifts$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 19 | $1,562 |
| Alcon | 24 | $1,207 |
| Sun Pharmaceutical Industries Inc. | 30 | $915 |
| Novartis | 23 | $528 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $390 |
| Dompe US, Inc. | 8 | $359 |
| Kala Pharmaceuticals, Inc. | 18 | $273 |
| Bausch & Lomb Americas Inc. | 8 | $222 |
| Oyster Point Pharma, Inc. | 5 | $192 |
| Rxsight Inc | 3 | $137 |
| Harrow Eye, LLC | 4 | $108 |
| Amgen | 6 | $101 |
| Mallinckrodt Enterprises LLC | 4 | $100 |
| AbbVie(2 entities) | 3 | $61 |
| Mallinckrodt Hospital Products Inc. | 2 | $47 |
| Shire North American Group Inc | 3 | $44 |
| Sight Sciences, Inc. | 3 | $43 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $40 |
| Ocular Therapeutix, Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 1 | $31 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$373
- XIIDRA$231
- iDose$178
- iDoseTR$157
- Clareon PanOptix Pro$146
- Clareon$146
- IACCESS$140
- iStent inject W$140
- TYRVAYA$125
- iStent inject Trabecular Micro-Bypass Stent System$119
- Hydrus Microstent$115
How this compares
$6,479 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 132 | $151,160 |
| MieboPerfluorohexyloctane/Pf | 67 | $50,975 |
| XiidraLifitegrast | 31 | $50,468 |
| CequaCyclosporine | 60 | $45,816 |
| Cyclosporine | 50 | $36,638 |
| ZirganGanciclovir | 36 | $31,762 |
| Prednisolone Acetate | 410 | $23,726 |
| TyrvayaVarenicline Tartrate | 19 | $14,690 |
| VevyeCyclosporine | 12 | $8,704 |
| ValacyclovirValacyclovir Hcl | 66 | $7,266 |
| Ketorolac Tromethamine | 164 | $6,053 |
| MoxifloxacinMoxifloxacin Hcl | 143 | $5,167 |
| Ofloxacin | 216 | $4,003 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 45 | $3,621 |
| ErythromycinErythromycin Base | 128 | $3,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $61 | $151,160132 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Zirgan | $222 | $133,205134 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $915 | $45,81660 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $192 | $14,69019 claims |
| Harrow Eye, LLCVevye | $108 | $8,70412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Tucson
- Martin WorrallTucson$12K
- Brock BakewellTucson$12K
- Sean GarrityTucson$11K
- Andreas GonzalezTucson$11K
- Lynn PolonskiTucson$9K
- Joseph JulianoTucson$9K
- Ajay SananTucson$8K
- Michael DiesenhouseTucson$7K
- Rachel HuynhTucson$6K
- Patrick TsaiTucson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.